Baillie Gifford & Co

Baillie Gifford & Co’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Baillie Gifford & Co’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,711	Closed	-$1.34K	–	459
2023 Q1	$1.34K	Hold	3,711	–	–	﹤0.01%	440
2022 Q4	$3.29K	Hold	3,711	–	–	﹤0.01%	463
2022 Q3	$6K	Sell	3,711 -603	-14%	-$1.37K	﹤0.01%	441
2022 Q2	$9K	Hold	4,314	–	–	﹤0.01%	427
2022 Q1	$10K	Hold	4,314	–	–	﹤0.01%	438
2021 Q4	$20K	Hold	4,314	–	–	﹤0.01%	380
2021 Q3	$33K	Sell	4,314 -838	-16%	-$7.11K	﹤0.01%	313
2021 Q2	$50K	Sell	5,152 -379	-7%	-$3.02K	﹤0.01%	288
2021 Q1	$46K	Buy	5,531 +422	+8%	+$4.46K	﹤0.01%	280
2020 Q4	$35K	Buy	+5,109	New	+$41K	﹤0.01%	285

Other funds holding SRNE

SlateStone Wealth Jupiter, Florida $1.21B AUM 21.86% 1-Year Est. Return

KLCM Advisors Milwaukee, Wisconsin $1.15B AUM 34.45% 1-Year Est. Return

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

Ogorek Anthony Joseph Williamsville, New York $365M AUM 18.21% 1-Year Est. Return

Russell Investments Group

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Trust Company of Vermont Brattleboro, Vermont $2.4B AUM 18.8% 1-Year Est. Return

Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return